Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Harvard Business School
Baxter
Johnson and Johnson
Mallinckrodt
AstraZeneca

Last Updated: October 15, 2019

DrugPatentWatch Database Preview

Drugs in Development Information for CHS-828

See Plans and Pricing

« Back to Dashboard

Drug Development Status for CHS-828: Patents, clinical trial progress, indications

CHS-828 is an investigational drug.

There have been 14 clinical trials for CHS-828. The most recent clinical trial was a Phase 3 trial, which was initiated on May 21st 2017.

The most common disease conditions in clinical trials are Psoriasis, Arthritis, Rheumatoid, and Marijuana Abuse. The leading clinical trial sponsors are Coherus Biosciences, Inc., Baxalta US Inc., and Daiichi Sankyo Co., Ltd.

There are seventeen US patents protecting this investigational drug and two hundred and forty-nine international patents.

Recent Clinical Trials for CHS-828
TitleSponsorPhase
Improving Pain Control in Paraesophageal Hernia Repair: Intravenous Lidocaine Versus PlaceboAtrium HealthPhase 4
Haloperidol Versus Ondansetron for Cannabis Hyperemesis Syndrome (HaVOC)Queen's UniversityPhase 4
Study to Assess the Pharmacokinetic and Pharmacodynamic Bioequivalence of CHS-1701 With NeulastaCoherus Biosciences, Inc.Phase 1

See all CHS-828 clinical trials

Clinical Trial Summary for CHS-828

Top disease conditions for CHS-828
Top clinical trial sponsors for CHS-828

See all CHS-828 clinical trials

US Patents for CHS-828

Drugname Patent Number Patent Title Patent Assignee Estimated Expiration
CHS-828   See Pricing Compounds and compositions for the inhibition of NAMPT Forma TM, LLC (Watertown, MA) Genentech, Inc. (South San Francisco, CA)   See Pricing
CHS-828   See Pricing Compounds and compositions for the inhibition of NAMPT FORMA TM, LLC (Watertown, MA) Genentech, Inc. (South San Francisco, CA)   See Pricing
CHS-828   See Pricing N-cyano-N'-pyridylguanidines as serotonin antagonists Leo Pharmaceutical Products Ltd. (Ballerup, DK)   See Pricing
CHS-828   See Pricing Cyanoguanidine prodrugs Leo Pharmaceutical Products Ltd. A/S (Ballerup, DK)   See Pricing
CHS-828   See Pricing Cyanoguanidine prodrugs LEO Pharma A/S (Ballerup, DK)   See Pricing
>Drugname >Patent Number >Patent Title >Patent Assignee >Estimated Expiration

International Patents for CHS-828

Drugname Country Document Number Estimated Expiration Related US Patent
CHS-828 Argentina 082885 2030-09-03   See Pricing
CHS-828 Australia 2011295725 2030-09-03   See Pricing
CHS-828 Brazil 112013004773 2030-09-03   See Pricing
CHS-828 Canada 2810038 2030-09-03   See Pricing
CHS-828 Chile 2013000588 2030-09-03   See Pricing
>Drugname >Country >Document Number >Estimated Expiration >Related US Patent

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKesson
Colorcon
Medtronic
McKinsey
Mallinckrodt
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.